Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance by Hennequart, Marc et al.
Research Article
Constitutive IDO1 Expression in Human Tumors Is
Driven by Cyclooxygenase-2 and Mediates
Intrinsic Immune Resistance
MarcHennequart1,2, Luc Pilotte1,2, Stefania Cane1,2, Delia Hoffmann1,2,Vincent Stroobant1,2,
Etienne De Plaen1,2, and Beno^t J. Van den Eynde1,2,3
Abstract
Tumors use various mechanisms to avoid immune destruc-
tion. Cyclooxygenase-2 (COX-2) expression may be a driver of
immune suppression in melanoma, but the mechanisms
involved remain elusive. Here, we show that COX-2 expression
drives constitutive expression of indoleamine 2,3-dioxygenase 1
(IDO1) in human tumor cells. IDO1 is an immunosuppressive
enzyme that degrades tryptophan. In a series of seven human
tumor lines, constitutive IDO1 expression depends on COX-2
and prostaglandin E2 (PGE2), which, upon autocrine signaling
through the EP receptor, activates IDO1 via the PKC and PI3K
pathways. COX-2 expression itself depends on the MAPK path-
way, which therefore indirectly controls IDO1 expression. Most
of these tumors carry PI3K or MAPK oncogenic mutations,
which may favor constitutive IDO1 expression. Celecoxib treat-
ment promoted immune rejection of IDO1-expressing human
tumor xenografts in immunodeﬁcient mice reconstituted with
human allogeneic lymphocytes. This effect was associated with a
reduced expression of IDO1 in those ovarian SKOV3 tumors
and an increased inﬁltration of CD3þ and CD8þ cells. Our
results highlight the role of COX-2 in constitutive IDO1 expres-
sion by human tumors and substantiate the use of COX-2
inhibitors to improve the efﬁcacy of cancer immunotherapy,
by reducing constitutive IDO1 expression, which contributes to
the lack of T-cell inﬁltration in "cold" tumors, which fail to
respond to immunotherapy. Cancer Immunol Res; 5(8); 695–709.
2017 AACR.
Introduction
Clinical results from cancer therapy based on the stimulation of
antitumor immune responses has introduced a paradigm shift in
oncology. By releasing brakes that repress T lymphocytes, anti-
bodies able to block inhibitory receptors CTLA-4 or PD1
expressed at the surface of T cells can unleash antitumor immu-
nity, inducing durable tumor responses and improving survival
of advanced cancer patients (1). However, this favorable out-
come is observed in only 20% to 40% of patients. In other
patients, tumors appear to establish an immunosuppressive
microenvironment that prevents the action of antitumor T
lymphocytes. Further progress therefore depends on our ability
to understand and target these immunosuppressive mechanisms,
which are likely manifold and involve a variety of cellular and
molecular pathways.
Tryptophan catabolism has emerged as a factor orchestrating
immunosuppression in the tumor microenvironment. Aberrant
tumoral expression of cytosolic tryptophan-degrading enzyme
indoleamine 2,3-dioxygenase 1 (IDO1) in tumors results in rapid
conversion of tryptophan into kynurenine. The resulting micro-
environment, depleted in tryptophan and enriched in kynure-
nine, is immunosuppressive (2, 3). Indeed, tryptophan shortage
induces an arrest of T-lymphocyte proliferation, apparently linked
to the induction of a GCN2-mediated integrated stress response,
whereas kynurenine and other tryptophan catabolites can induce
T-cell apoptosis and/or favor the induction of regulatory T cells
(4–6). In humans, IDO1 is normally expressed only in a restricted
set of cells, including placental endothelial cells and mature
dendritic cells. Studies in mice demonstrated the key role of
placental IDO1 to prevent immune rejection of the fetus (7, 8).
IDO1expression inmature dendritic cells is believed to contribute
to the retro-control of immune responses (9). In line with this
function is the fact that IDO1 expression can be induced in most
tissues and cell types upon exposure to IFNg (10, 11). Because
IFNg is produced by T lymphocytes at the peak of their response,
the ensuing induction of IDO1 ensures a negative feedback of the
T-cell response. Indeed, IDO1-deﬁcientmice develop exacerbated
autoimmune pancreatitis triggered by the injection of Freund's
adjuvant (12).
The availability of small-molecule inhibitors able to block
IDO1 enzymatic activity allowed conﬁrmation of the immuno-
suppressive role of tumor IDO1: in a number of preclinical
models, the inhibition of IDO1 activity resulted in antitumor
effects that were synergistic with various immunotherapy
approaches, including vaccination and checkpoint blockade
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(13, 14). In a wide range of human tumors, IDO1 expression was
also correlated with a worse prognosis and a reduced T-cell
inﬁltration (15–17). These results have prompted the clinical
development of IDO1 inhibitors, which are now inphase III trials.
Although mouse studies highlighted increased IDO1 expres-
sion in tumor-draining lymph nodes, this was not observed in
humans (9). In addition, mechanistic studies indicated that the
relevant IDO1 for tumor-induced immune suppression was pres-
ent at the tumor site (18). There are distinct patterns of IDO1
expression in human tumors (9). Anumber of tumors show IDO1
expression associated with a T-cell inﬁltrate and signs of inﬂam-
mation. This expression likely results from induction by IFNg
produced by inﬁltrating T cells. Such a pattern of expression,
indicative of adaptive immune resistance, has been observed for
other immune counter-regulatory molecules such as PD-L1 (19).
In contrast, many human tumors express IDO1 in the absence of
any inﬂammation and T-cell inﬁltrate, representing a state of
intrinsic immune resistance (3, 9). This may account for the
clinically relevant group of "cold" or "noninﬂamed" tumors,
which fail to respond to checkpoint inhibitors due to the lack of
T-cell inﬁltrate. This pattern of IDO1 expression is recapitulated in
a number of human tumor cell lines that express IDO1 in a
constitutive manner, i.e., in the absence of IFNg (13). Little is
known about the signaling mechanisms accounting for constitu-
tive IDO1 expression in human tumors.
Here, we report the characterization of the signaling pathways
accounting for constitutive IDO1 expression in a series of human
tumor cell lines. Our results show that autocrine prostaglandin E2
triggers PKC and PI3K signaling, which in turn leads to IDO1
transcription. PGE2 production results from constitutive expres-
sion of COX-2 triggered byMAPK signaling. These tumors harbor
oncogenic mutations in one or several of these signaling path-
ways, which likely contribute to constitutive IDO1 expression
making up an immunosuppressive tumor phenotype. Blocking
COX-2 activity in vivo prevents IDO1 expression and restores
immune rejection of human tumors in a mouse model recon-
stituted with human lymphocytes. Our results provide a mech-
anistic explanation for the reported role of COX-2 in tumor
evasion of immunity (20–22). Our results also highlight a link
between oncogenic signaling and immunosuppression in
human tumors and suggest the use of COX-2 inhibitors as
immune modulators to increase the clinical efﬁcacy of cancer
immunotherapy.
Materials and Methods
Cancer cell lines
KUL98-MELA and KUL98-MELB are melanoma nodules that
were obtained from UZ Leuven Gasthuisberg in 2003 and 2004,
respectively. Authentication by DNA ﬁnger printing was last done
in September 2014. Mycoplasma tests were done in July 2004 for
KUL98-MELA and April 2005 for KUL98-MELB. LB919-SCCHN
was derived at the Ludwig Institute Brussels Branch from a patient
sample donated by Cliniques universitaires Saint-Luc in February
1994 and tested for mycoplasma in April 1994. No authentication
was carried out. LB1610-MEL was derived at the Ludwig Institute
Brussels Branch from a patient sample donated by Cliniques
universitaires Saint-Luc in July 1997 and last tested formycoplasma
in November 2012. Authentication was last carried out in May
2011 by DNA ﬁnger printing. LB188-SAR was derived at the
Ludwig Institute Brussels Branch from a sample donated by
Ho^pital Jolimont in May 1991 and last tested for mycoplasma in
January 1992. No authentication was done. LS411N was received
from collaborators in Lausanne in 1990. Neither mycoplasma test
nor authentication has been done. NCI-H596 was purchased
from the ATCC in 1995 and last tested for mycoplasma in Novem-
ber 2012. No authentication has been carried out. U87 was
purchased from CLS Cell Lines Services GmbH in 2011. Neither
mycoplasma test nor authentication has been done. A172 was
purchased from Antisense Pharma GmBH in 2004 and last tested
for mycoplasma in November 2012. No authentication has been
carried out. MZ-CHA-3 was received from collaborators in Mainz
in 1991 and last authenticated in May 2011 by DNA ﬁnger
printing. No mycoplasma test has been done. SKOV3 was pur-
chased from CLS Cell Lines Services GmbH in 2014 and last
authenticated by DNA ﬁnger printing in August 2016. No myco-
plasma test has been done. Cells were cultured under standard
conditions. For PGE2 metabolite quantiﬁcation, cells were cul-
tured in X-VIVO 15 medium (Lonza). All mycoplasma tests were
done by qPCR.
Compounds
LY294002 (4402-4) (used at 20 mmol/L for 24 hours) and R0-
31-8425 (557514) (20 mmol/L for 24 hours) were obtained from
Calbiochem. GDC0941 (957054-33-0) (5 mmol/L for 72 hours)
was bought from Axon Medchem. A66 (S2636) (20 mmol/L for
72 hours), TGX221 (S1169) (30 mmol/L for 72 hours), MK2206
(S1078) (10 mmol/L for 72 hours), and ruxolitinib (S1378) were
bought from Selleckchem. CAY10598 (13281) (10 mmol/L for 24
hours)was obtained fromCaymanChemicals. H-89 (B1427) and
rapamycin (R3781) (200 nmol/L for 8 hours) were bought from
Sigma. PLX4032 (S1267)(10 mmol/L for 72 hours) was bought
from Selleckchem. U0126 (BML-EI282-0001) (20 mmol/L for 72
hours), and SB203580 (EI-286-0005) (10 mmol/L for 72 hours)
were obtained from ENZO. Celecoxib (used at 5 mg/mL) was
bought by prescription from Pﬁzer. MF63 (10 mmol/L) was
bought fromAbMole BioScience. AH6809 (14050), GW627368X
(10009162) both used at 10 mg/mL were obtained from Cayman
Chemicals. Celecoxib, MF63, AH6809, and GW627368X were
added twice (days 0 and 2) on a 3-day period. Epacadostat was
obtained from Chemietek. Human recombinant IL1b (200-01B)
(1 mg/mL for 12 hours) and human IFNg (300-02) were bought
from Peprotech. Anakinra (Kineret 10 mg/0.67 mL), used at
50 mg/mL for 72 hours, was bought by prescription from Sobi.
Western blot
Cells were lysed in homemade lysis buffer [0.1% SDS, 1%
deoxycholic acid, 0.5% NP40 complemented with protease and
phosphatase inhibitors (Roche)]. Proteins were separated on
precast NuPage 4% to 12% Bis-Tris gels (Invitrogen) in MOPS
running buffer. Dry transfer was done with the iBlot from
Thermo Scientiﬁc. Membranes were blocked in PBS or TBS
containing 5% dry milk and 0.1% Tween 20 and then probed
with the primary antibodies at 4C overnight. Images were
acquired by Fusion Fx camera from Vilber Lourmat. Quantiﬁ-
cation was obtained with the Bio-1D (version 15.06b) software
from Vilber Lourmat.
p-AKT (Ser 473) rabbit mAb (#4060 from Cell Signaling
Technology), AKT rabbit mAb (#4691 from Cell Signaling Tech-
nology), p-GSK3b (Ser9) rabbit mAb (#5558 from Cell Signaling
Technology), GSK3b mouse mAb (#9832 from Cell Signaling
Technology), p-p70S6K (T389) rabbit mAb (#9234 from Cell
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Signaling Technology), p70S6K rabbit mAb (#2780 from Cell
Signaling Technology), p-CREB (Ser133) rabbit mAb (#9191
from Cell Signaling Technology), CREB rabbit mAb (#9197 from
Cell Signaling Technology), p-p44/42 MAPK (ERK1/2) (Thr202/
Tyr204) rabbit mAb (#4370 from Cell Signaling Technology),
p44/42 MAPK rabbit polyclonal Ab (#9102 from Cell Signaling
Technology), b-catenin rabbit mAb (#8480 from Cell Signaling
Technology), p-STAT3 (Y705) rabbit mAb (#9145 from Cell
Signaling Technology), STAT3 rabbit mAb (#4904 from Cell
Signaling Technology), p-STAT1 (Tyr 701) rabbit polyclonal Ab
(#9171 from Cell Signaling Technology), and STAT1 rabbit
polyclonal Ab (#9172) were diluted at 1/1,000. IDO1 mouse
antibody (4.16H1 clone 7) was homemade and used at 2 mg/mL
(9). Actin mouse antibody (A5441) bought from Sigma was used
at 1/10,000. Vinculin mouse mAb (hVIN-1) antibody (V9131)
bought from Sigma was used at 1/2,000.
Secondary antibodies were incubated 1 hour at room temper-
ature before revelation with the cheluminescent substrate West
Pico SuperSignal sold by Thermo Scientiﬁc. Anti-rabbit HRP-
linked IgG (#7074 from Cell Signaling Technology) was used at
1/3,000, and anti-mouse HRP-conjugated IgG (HAF007 from
R&D Systems) was used at 1/5,000.
qPCR
RNA was extracted by Tripure (Roche), and the retro-transcrip-
tion was done with the revertAid kit from Thermo Scientiﬁc
(K1691). RT-qPCRwas performed with the Takyon Rox probe core
kit dTTP from Eurogentec (UF-RPCT-C0201). RT-qPCR for IDO1
(Forward: GGTCATGGAGATGTCCGTAA; Reverse: ACCAATAGA-
GAGACCAGGAAGAA; Probe: CTGTTCCTTACTGTCAACTCTC-
CAAGAAACTG), mPGES1 (F: GCTGGTCATCAAGATGTACG; R:
CCAGGTAGGCCACGGTGTCT), EP2 (F: CCACCTCATTCTCCT-
GGCTA; R: CGACAACAGAGGACTGAACG), EP4 (F: TGGTATG-
TGGGCTGGCTG; R: GAGGACGGTGGCGAGAAT), and GAPDH
(F: TCAACGACCACTTTGTCAAGC; R: CCAGGGGTCTTACT-
CCTTGG;Probe:CCTGGTATGACAACGAATTTGGCTACAGC)was
performed with an elongation condition of 62C for 1minute. RT-
qPCR for COX-2 (F: CAGGCTAATACTGATAGGAGAGA; R: TTGA-
CAACTATCAACATAAAGACCAGT), EP1 (F: GGTATCATGGTG-
GTGTCGTG; R: GGCCTCTGGTTGTGCTTAGA), EP3 (F: CTTCGC-
ATAACTGGGGCAAC; R: TCTCCGTGTGTGTCTTGCAG), IL1b
(F: CTGCCCACAGACCTTCCA; R: GGACCAGACATCACCAAGC;
Probe: AATGACCTGAGCACCTTCTTTCCTT), IL8 (F: CTGAGACT-
GATTGAGAGTGGA; R: GTGTTGAAGTAGATTTGCTTGAAG;
Probe:AGCTCTGTCTGGACCCCAAGGAAAAC)CD3e (F:GGCAA-
GATGGTAATGAAGAAATGG; R: AGGGCATGTCAATATTACTG-
TGGTT), CD8b (F: CAGCTGAGTGTGTGGTTGATTTCC; R: ACC-
GGCACACTCTCTTCTTGA; Probe: CCCACCACTGCCCAGCC-
CAC), and Actin (F: GGCATCGTGATGGACTCCG; R: GCTG-
GAAGGTGGACAGCGA; Probe: TCAAGATCATTGCTCCTCCT-
GAGCGC) was performed with an elongation condition of 60C
for 1 minute.
Mouse experiments
NSG mice (from The Jackson Laboratory) were bred at the
animal facility of the Ludwig Institute for Cancer Research, Brus-
sels, Belgium. Handling of mice and experimental procedures
were conducted in accordance with national and institutional
guidelines for animal care. NSG mice were injected subcutane-
ously with 4 106 SKOV3 or LS411N cells. After 7 days (d-3), the
tumors were measured and randomized groups of mice (9 for
SKOV3 and 8 for LS411N) were treated or not with celecoxib
(10 mg/kg once a day) and/or IDO1 inhibitor epacadostat
(100 mg/kg twice a day) by oral gavage (d-3). Control mice
received methocel (100 mL). Three days later (d0), the mice were
injected or not with 3  106 human allogeneic peripheral blood
mononuclear cells (PBMC; d0) in the tail vain. Under those
conditions, mice did not develop graft-versus-host disease
(GVHD)before day 40. Tumorsweremeasured at regular intervals
with an electronic caliper. Mice were sacriﬁced after 40 days and
tumors were resected and frozen for immunochemistry, RNA, and
protein extraction. RNA and proteinswere extracted after crushing
the tumors in liquid nitrogen.
Isolation of PBMCs
PBMCs were puriﬁed from the blood of a hemochromatosis
donor (LB2419), courtesy of Saint-Luc University Hospital, by
centrifugation on a Lymphoprep gradient and then frozen at
80C.
Lentivirus production and transduction of target cells
Recombinant lentiviruses were produced by transient cotrans-
fection of 293T cells in 100-mm tissue culture disheswith 4.2, 2.1,
and 2.5 mg of pGAG-POL, pREV, and PVSV-G, respectively, for
viral encapsidation. At the same time, the shSTAT3 pGIPZ vector
(V3LHS_641817 from Dharmacon) or the pGIPZ empty vector
(RHS4351 from Dharmacon) was transfected too. The transfec-
tion was performed using the calcium phosphate precipitation
method. The medium was replaced 4 hours later and virus-
containing supernatants were harvested after 24, 48, and 72 hours
after transfection. Cancer cells were then plated in a 6-well plate
and 500 mL of viral supernatant and 500 mL of fresh media were
added after 4 hours. Seventy-two hours later, supernatants were
discarded and fresh media were added with 3 mg/mL of puromy-
cin for selection.
Tryptophan and kynurenine quantiﬁcation
Cells were treated with 5 mg/mL of celecoxib or 10 mg/mL of
GW627368X every 2 days, 20 mmol/L LY294002 or 10 mmol/L
MK2206, 20mmol/L Ro-31-8425, or 10mmol/L SB203580 every 3
days. Cell culture supernatants were harvested up to 7 days after
plating and analyzed by HPLC as previously described (23). Time
point 0 corresponds to cell-free medium.
PGE2 metabolite detection assay
Cells were cultured in X-VIVO 15 medium (Lonza) for 5 days
before supernatants were collected and PGE2metabolites (13,14-
dihydro-15-keto PGA2 and 13,14-dihydro-15-keto PGE2) quan-
tiﬁed by a prostaglandin E metabolite EIA kit from Cayman
Chemical. Control corresponds to cell-free X-VIVO 15 medium.
Quantiﬁcation of IL1b
KUL98-MELA and KUL98-MELB cells were cultured in X-VIVO
15 medium for 3 days. The supernatant was harvested, and IL1b
was quantiﬁed with the human IL1b ELISA Ready-SET-Go from
Affymetrix-eBioscience (88-7261-88).
siRNA
siRNA (100nmol/L) directed againstCTNNB1 and the negative
control siRNA diluted in Opti-MEM medium (ThermoFisher
Scientiﬁc) were ﬁrst incubated with lipofectamin 2000 (Invitro-
gen) before adding the lipofectamin-siRNAmixture on the cancer
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cells for 6 hours. Themediumwas changed after 6 hours, and cells
harvested after 48 hours were analyzed. CTNNB1 Silencer vali-
dated siRNA (AM51331) and Silencer Negative Control siRNA
(AM4611) were purchased at Ambion ThermoFisher Scientiﬁc.
RNAseq
RNA samples were prepared from cell lines using the guanidi-
nium isothiocyanate/cesium chloride procedure (24). Mutations
in KUL98-MELA, KUL98-MELB, MZ-CHA-3, and LB1610-MEL
cell lines were visually detected in selected genes from RNAseq
data performed on an in-house SOLID platform. Mutations in
LB188-SAR and LB919-SCCHN cell lines were visually detected in
selected genes from RNAseq data performed on an Illumina
TrueSeq platform. Coverage was of 470M reads (2  125 bp
paired end) at Beckman Coulter Inc.
Cancer cell line encyclopedia
Expression data and mutation data were extracted from the
Cancer Cell Line Database from the Broad Institute in collabo-
ration with Novartis. The database was validated by quantifying
IDO1 expression by RT-qPCR in a series of cancer cell lines
available at the Ludwig Institute. Signiﬁcance of the comparisons
between the IDO1-positive and IDO1-negative populations was
assessed by unpaired t-test with Welch correction (unequal var-
iance, F test was signiﬁcant). Correlation between IDO1 andCOX-
2 or mPGES1 was evaluated by a Spearman correlation test. The
differences in proportions between IDO1-positive mutated cell
lines and IDO1-positive nonmutated cancer cell lines were tested
by a unilateral Fisher test. The mutations taken in account for this
study were mined from the CCLE database and located in onco-
genic hotspots: PI3K, AKT, PTEN, HRAS, BRAF, NRAS, and KRAS.
SKOV3 and lymphocyte proliferation
Onday0, SKOV3 cellswere plated in a 96-wellﬂat bottomplate
and treated with different concentrations of epacadostat. Human
allogeneic PBMCs (LB2419) were stimulated with CD3þ/CD28þ
beads and IL2 for 10 minutes before coculturing them with
SKOV3 cells at a 1:2 SKOV3/PBMC ratio. On day 1, supernatants
were harvested for tryptophan/kynurenine quantiﬁcation assay
by HPLC and 3H-thymidine was added in each well. On day 2,
PBMC proliferation was measured by thymidine incorporation
(TopCount counter Perkin Elmer). In a separate experiment,
human allogeneic PBMCs (LB2419) prestimulated with CD3þ/
CD28þ beads and IL2 for 10 minutes were cultivated either in
freshmedium supplemented or not with celecoxib 5 mg/mL, or in
conditioned medium from SKOV3 cells cultured 72 hours in the
presence or absence of celecoxib 5 mg/mL. On day 1, 3H-thymi-
dine was added and PBMC proliferation was measured as above.
On day 2, the supernatants were also used to quantify the Th1 and
Th2 cytokines with the Bio-Plex Pro Human cytokine Th1/Th2
assay from Bio-Rad.
Immunohistochemistry
Tumors were extracted at the end point of each experiment and
frozen. Frozen sections (5 mm) were incubated 5 minutes in 4%
formaldehyde for ﬁxation. Endogenous peroxidases were blocked
with DAKO peroxidase blocking solution for 15 minutes, and
nonspeciﬁc stainingwaspreventedby incubation in a5%BSA, 2%
milk, and 1% human IgG solution in TBS-T for 1 hour. Sections
were then incubated with a 1/200 dilution in REAL antibody
diluent (#S2022 from Agilent) of the rabbit anti-human CD3
antibody (Clone SP7, # ab16669 fromAbcam, concentration 1–3
mg/mL) or 1/200 dilution of the mouse anti-human CD8 anti-
body (Clone C8/144B, #M710301 from Agilent, concentration
157 mg/L). The anti-mouse goat polymer HRP (#K4005 from
Agilent) or the anti-rabbit goat polymer-HRP (#K4009 from
DAKO)was then addedand incubated for 1hour. Finally, sections
were stainedwith theAECþ chromogenic substrate (#K4005 from
Agilent) for 20 minutes and counterstained with a solution of
hematoxylin for 5minutes. Stained sections were digitalized with
a Pannoramic P250 Flash III slide scanner (3DHISTECH) and
were analyzed with CaseViewer (3DHISTECH). Sections were
quantiﬁed with the ImageJ software.
Statistical method
For the analysis of the effect of the different inhibitors, an
unpaired t-test was done; the Welch correction was applied in the
caseswhere the variancewas not equal. The P values are annotated
as follows: , P < 0.05; , P < 0.01; , P < 0.005; and , P <
0.0001. For the mouse in vivo experiments, a nonparametric
"AnovaWilcoxon each pairs" test was done on the last time point.
Results
Autocrine PGE2 drives IDO1 expression in human melanoma
We selected a series of human cancer cell lines that consti-
tutively express IDO1 and, accordingly, degrade tryptophan
and produce kynurenine in equimolar amounts (13) (Supple-
mentary Table S1). We focused our initial experiments on a
BRAF V600E-mutated melanoma cell line, named KUL98-
MELA. Because IFNg induces IDO1 expression, we ﬁrst consid-
ered the possibility that KUL98-MELA might display a consti-
tutive activation of the IFNg signaling pathway, which entails
JAK1/JAK2-mediated phosphorylation of STAT1. We observed
that ruxolitinib, a JAK1/JAK2 inhibitor, did not reduce the
constitutive levels of IDO1 transcripts in KUL98-MELA cells
(Supplementary Fig. S1A), although it prevented both IDO1
induction and STAT1 phosphorylation triggered by addition of
IFNg (Supplementary Fig. S1B). These results indicated that
constitutive IDO1 expression was not triggered by the IFNg
signaling pathway in these melanoma cells.
COX-2 shapes the immunosuppressive tumor microenviron-
ment of mouse melanoma, although the downstream mechan-
isms remain unclear (20). In addition, PGE2 contributes to
induction of IDO1 expression in dendritic cells during the mat-
uration process (25). These observations prompted us to consider
that the PGE2 signaling pathwaymight be involved in constitutive
IDO1 expression by human tumor cells. We observed that cel-
ecoxib, a COX-2 speciﬁc inhibitor, reduced the levels of IDO1
transcripts by3-fold inKUL98-MELA cells (Fig. 1A).Moreover, the
IDO1 protein was not detectable in treated cells, which no longer
degraded tryptophan nor produced kynurenine (Fig. 1A and B).
As another means of preventing PGE2 formation, we then used
MF63, an inhibitor of membrane-associated PGE2 synthase
(mPGES1), and observed again a reduction of IDO1 transcripts
and protein levels (Fig. 1A). We then considered that PGE2 might
trigger autocrine signaling and investigated the expression of the
four isoforms of PGE2 receptors, EP1-4, on our melanoma cells.
We observed expression of EP4 transcripts (Fig. 1C). We therefore
inhibited EP4 with a competitive antagonist, GW627368X, and
observed again a decrease in IDO1 transcripts, IDO1 protein, and
Hennequart et al.
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enzymatic activity in the treated melanoma cells (Fig. 1A and B).
Altogether, these results suggested that constitutive IDO1 expres-
sion in KUL98-MELA cells was triggered by an autocrine loop of
PGE2 secretion. In linewith this,weobserved theproductionof up
to 400 pg/mL of PGE2 metabolites in the culture supernatant of
those cells (Fig. 1D). Moreover, addition of this PGE2-containing
supernatant to celecoxib-treated KUL98-MELA cells restored
IDO1 expression by these cells (Fig. 1E).
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Figure 1.
Involvement of the PGE2 and PI3K
pathways in constitutive IDO1
expression.A,KUL98-MELA cellswere
treated for 3 days with different
inhibitors of the PGE2 pathway, RT-
qPCR, and Western blot analysis were
then performed. The number of IDO1
transcripts was reported to that of the
untreated cells, and the absolute
number of transcripts in the untreated
cells is indicated on the histogram.
This representation is used throughout
the manuscript. B, Tryptophan and
kynurenine concentrations were
measured by HPLC. C, Quantiﬁcation
by RT-qPCR of EP receptor transcripts
was performed on RNA extracted
from KUL98-MELA cells. D, PGE2
metabolite levels were measured in
supernatant from KUL98-MELA cells.
E, KUL98-MELA cells were treated
with celecoxib for 4 days. Every day
the culture mediumwas replaced with
fresh X-VIVO medium or with
24 h-culture supernatant of untreated
KUL98-MELA cells, both containing
fresh celecoxib. F, KUL98-MELA cells
were treated with PI3K pathway
inhibitors before RT-qPCR and
Western blot analysis. G, Tryptophan
and kynurenine concentrations were
measured by HPLC. Mean þ SD of
triplicates from one out of three
experiments. See also Supplementary
Figs. S1 and S2.
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Involvement of the PI3K and PKC signaling pathways
To characterize the link between PGE2 signaling and IDO1
expression, we investigated the signaling pathways downstream
of the EP receptors, which areGprotein–coupled receptors able to
activate the PKA, PI3K, and PKC pathways (26–28).
H-89, a competitive inhibitor of PKA, did not reduce IDO1
transcript levels in KUL98-MELA cells, although it reduced phos-
phorylation of PKA downstream effector CREB (Supplementary
Fig. S1C).
In contrast, LY294002, a pan-PI3K inhibitor, reduced IDO1
transcript levels and abolished both IDO1 protein expression and
enzymatic activity (Fig. 1F and G). Similar results were obtained
using GDC-0941, a pan-PI3K inhibitor used in clinical trials (ref.
29; Fig. 1F). PI3K-subunit speciﬁc inhibitors A66 (p110a inhib-
itor) and TGX221 (p110b inhibitor) also reduced IDO1 transcript
levels (Fig. 1F). All these inhibitors effectively reduced phosphor-
ylation of AKT, a downstream effector of the PI3K pathway
(Supplementary Fig. S2A–S2D). MK2206, an AKT inhibitor, also
reduced IDO1 expression and enzymatic activity (Fig. 1F and G).
Because AKT can phosphorylate both GSK3b and p70S6K, we
assessed the phosphorylation of these proteins in treated cells.
Although p70S6K phosphorylation was abrogated by MK2206
treatment,GSK3bphosphorylationwasnot affected (Supplemen-
tary Fig. S2E). We observed similar results with the different PI3K
inhibitors (Supplementary Fig. S2A–S2D). These results sug-
gested that, although EP receptors signal through the PI3K path-
way, this pathway is not involved in GSK3b phosphorylation, but
rather activates mTOR, consistent with the fact that p70S6K
phosphorylation is abrogated by all the PI3K and AKT inhibitors.
This was conﬁrmed by treatment of KUL98-MELA cells with
rapamycin, which led to reduction of IDO1 expression (Fig.
1F) and abrogation of phospho-p70S6K (Supplementary Fig.
S2F). We suggest a possible signaling pathway for constitutive
IDO1 expression in human tumors in Fig. 2.
Finally, we tested the PKC pathway, which can inactivate
GSK3b by phosphorylating its serine 9 in the same manner as
PI3K (30). Upon treatment with pan-PKC inhibitor Ro-31-8425,
KUL98-MELA cells reduced their IDO1 expression and enzymatic
activity and dephosphorylated GSK3b (Fig. 3A–C). GSK3b reg-
ulates a number of transcription factors, including b-catenin,
which binds the IDO1 promoter (30, 31). Silencing b-catenin
with siRNA reduced levels of IDO1 transcript and protein (Fig.
3D).We conﬁrmed this PKC pathway to be independent from the
PI3K/AKT pathway described above, by testing a combination of
the AKT inhibitor MK2206 and the pan-PKC inhibitor Ro-31-
8425: we observed an additive inhibitory effect on IDO1 expres-
sion, indicating that both pathways act independently down-
stream of the EP4 receptor (Fig. 3E). Altogether, we conclude
that PGE2-triggered signaling involves both the PKC pathway,
which activates IDO1 via b-catenin, and the PI3K pathway, which
activates IDO1 via mTOR. The mTOR activation may depend on
the transcription factor ETV4/PEA3, which functions downstream
p p
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p38MAPK Figure 2.
Signaling pathway responsible for
constitutive IDO1 expression in human
cancer cells. The asterisk denotes
potential mutation sites that
contribute to constitutive expression
of IDO1. PTGS2 is the gene encoding
COX-2. Green phosphorylation
symbols in the PI3K/AKT and MAPK
pathways indicate an activating
process. Red phosphorylation
symbols indicate an inactivating
process such as the phosphorylation
of serine 9 of GSK3b by PKC and the
phosphorylation of b-catenin by the
active form of GSK3b, resulting in
b-catenin degradation by the
proteasome.
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of mTOR and binds the IDO1 promoter (32) (Fig. 2). Of note,
melanoma-intrinsic b-catenin signaling was found to be linked to
immune evasion and resistance to immunotherapies (33).
Activated MAPK pathways support constitutive COX-2
expression
Because KUL98-MELA cells harbor a BRAFV600Emutation, we
also investigated the role of the MAPK pathway in constitutive
IDO1 expression. We used a BRAF V600E inhibitor (PLX4032),
a MEK1/2 inhibitor (U0126) and a p38MAPK inhibitor
(SB203580). All reduced IDO1 expression in KUL98-MELA cells
(Fig. 4A andB). Because the expressionofCOX-2 is also controlled
by the ERK1/2 pathway, we alsomeasured COX-2 expression and
found that itwas reduced in cells treatedwith these inhibitors (34)
(Fig. 4C). In contrast, the PGE2 and PI3K pathway inhibitors we
used above did not reduceCOX-2 expression (Supplementary Fig.
S3). Altogether, these results suggest an indirect involvement of
the MAPK pathway in constitutive IDO1 expression, ensuring
constitutive expression of COX-2 to sustain autocrine production
of PGE2 (Fig. 2).
Autocrine IL1b supports PGE2 production and IDO1
expression
KUL98-MELB is another melanoma line derived from a differ-
ent metastasis from the same patient. KUL98-MELB cells do not
express IDO1. As compared to KUL98-MELA cells, they express
COX-2 at a similar level, but mPGES1 at a much lower level (Fig.
5A). Accordingly, they produce no PGE2 (Fig. 5B), likely explain-
ing why they do not express IDO1. To understand why KUL98-
MELB cells express less mPGES1 than KUL98-MELA, we consid-
ered IL1b, which can control expression of both COX-2 and
mPGES1, and we compared the expression of IL1b and its target
gene IL8 (35–37). We observed that KUL98-MELB cells expressed
less of IL1b and IL8 transcripts (Fig. 5C and D) and produced less
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Involvement of the PKC pathway. A,
KUL98-MELA cells were treated with a
pan-PKC inhibitor before RT-qPCR
and Western blot analysis. B, KUL98-
MELA cells treated for the indicated
times were analyzed by Western blot.
C, Tryptophan and kynurenine
concentrations were measured by
HPLC. D, b-catenin was silenced by
siRNA (CTNNB1) in KUL98-MELA cells
and Western blot analysis was
performed. E, KUL98-MELA cells were
incubated 72 hours with MK2206,
24 hours with Ro-31-8425 or 72 hours
with MK2206 supplemented with Ro-
31-8425 after 48 hours and expression
of IDO1 was analyzed by RT-qPCR.
Mean þ SD of triplicates from one out
of three experiments.
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IL1b in their supernatant (Fig. 5E). To determine whether this
lack of IL1b production was involved in the reduced mPGES1
and IDO1 expression by KUL98-MELB cells, we treated these
cells with recombinant IL1b and observed increases in IDO1,
COX-2, and mPGES1 expression (Fig. 5F). The observed IDO1
induction was blocked with the p38MAPK inhibitor SB203580,
but also with the EP4 inhibitor GW627368X (Fig. 5G). Hence,
IL1b contributes to COX-2 and mPGES1 expression, which in
turn allows PGE2 production and IDO1 expression. These
results suggest that in KUL98-MELA cells, besides the autocrine
PGE2 loop, an IL1b autocrine loop contributes to constitutive
COX-2 and mPGES1 expression and therefore indirectly sup-
ports IDO1 expression (Fig. 2). Accordingly, we observed that
blocking IL1b in KUL98-MELA cells with recombinant IL1ra,
anakinra, reduced expression of IL8, a classical IL1b target, but
also reduced IDO1 expression as well as COX-2 and mPGES1
expression (Fig. 5H and I).
PGE2 supports constitutive IDO1 expression by other human
cancer lines
So far we have demonstrated the importance of PGE2 and
downstream signaling pathways in the KUL98-MELA melanoma
line. Next, we tested whether this mechanism also accounted for
constitutive IDO1 expression in other human tumor lines, includ-
ing a cholangiocarcinoma line, a head and neck carcinoma line, a
sarcoma line, another melanoma line, an ovarian carcinoma line
and a non–small cell lung carcinoma line (Supplementary Table
S1). We observed a decrease in IDO1 expression upon treatment
of these lines with celecoxib (Fig. 6A). We also proﬁled the
expression of the four EP receptor isoforms in the tumor lines
(Supplementary Fig. S4A), and treated themwith the inhibitor of
the most expressed isoform. In all cases, the EP inhibitor
decreased IDO1 expression (Fig. 6B). We also observed that
CAY10598, an agonist of the EP4 receptor, restored IDO1 expres-
sion in celecoxib-treated SKOV3 cells (Fig. 6C). In addition, this
agonist was able to induce low levels of IDO1 in IDO1-negative
glioblastoma cell lines A172 and U87 (Fig. 6D). Finally, we
conﬁrmed the production of PGE2 by detecting the presence of
PGE2 metabolites in the supernatant of the 4 tumor lines that we
tested (Supplementary Fig. S4B). Therefore, we conclude that the
COX-2/PGE2 pathway is responsible for constitutive IDO1
expression in a wide range of different human cancer types.
We then mined the transcriptomics data of 1,041 different
human cancer cell lines from the Broad Institute, looking for
correlations between IDO1 expression and activation of the COX-
2/PGE2 axis. We ﬁrst took 21 of these cell lines, measured IDO1
expression by RT-qPCR, and matched the result with the value in
the RNAseq database (Supplementary Fig. S5A). This validation
allowedus to use percentile 80 as a cutoff for IDO1positivity, with
20% of tumor lines being positive. This was in line with our
previous work showing IDO1 expression in tumor cells in 3% to
56% of tumor samples depending of the type (9). We then
clustered the database according to percentile 20/80 to separate
IDO1-negative (below percentile 20) and IDO1-positive lines
(above percentile 80), and interrogated COX-2 and mPGES1
expression. We observed more expression of COX-2 andmPGES1
in the IDO1-positive group, but no correlationwith housekeeping
gene VINCULIN (Fig. 6E). Even though the number of samples
became limiting when we started analyzing the database per
histological tumor type, we also observed correlations between
IDO1 and COX-2 (PTGS2) or mPGES1 (PTGES) expression in six
different cancer histotypes (Supplementary Fig. S5B).
Most of the IDO1-expressing tumor cell lines we have charac-
terized in this work had mutations in genes of the PI3K or MAPK
pathways or of receptors leading to the activation of these path-
ways, such as ERBB2 (Supplementary Table S1). This suggested
that activation of the PI3K pathway downstream of the EP
receptors or of theMAPK pathway upstream of COX-2 expression
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Figure 4.
Involvement of the MAPK pathway. A, KUL98-MELA cells were treated with MAPK pathway inhibitors for 3 days before RT-qPCR and Western blot analysis.
B, Tryptophan and kynurenine concentrations were measured by HPLC. C, The same extracts as in A were used to quantify the transcripts of COX-2
by RT-qPCR. Mean þ SD of triplicates from one out of three experiments. See also Supplementary Figs. S2 and S3.
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Role of IL1b. A, RT-qPCR analysis of the expression of IDO1, COX-2, and mPGES1. B, PGE2 metabolite levels were measured. C, RT-qPCR analysis of the
expression of IL1b.D, IL8was quantiﬁed by RT-qPCR. E, Supernatants of KUL98-MELA andKUL98-MELB cellswere harvested and IL1bwas quantiﬁed by ELISA; fresh
medium was used as a control. F, KUL98-MELB cells were treated with IL1b for 12 hours before RT-qPCR analysis. G, KUL98-MELB cells were pretreated with
GW627368X or SB203580 at day 0. At day 3 the cells were treated with IL1b for 12 hours, with GW627368X or with SB203580.Western blots were then performed.
H, IL8 transcripts were quantiﬁed by RT-qPCR after treatment of KUL98-MELA cells with anakinra. I, KUL98-MELA cells were treated 72 hours with anakinra
before RT-qPCR analysis. Mean þ SD of triplicates from one out of three experiments.
Oncogenic Signaling Drives Constitutive IDO1 Expression
www.aacrjournals.org Cancer Immunol Res; 5(8) August 2017 703
on March 1, 2018. © 2017 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Published OnlineFirst July 21, 2017; DOI: 10.1158/2326-6066.CIR-16-0400 
Number of IDO1 transcripts per cell 
reported to the untreated condition (%)
Number of IDO1 transcripts per cell 
reported to the untreated condition (%)
Celecoxib (COX-2i) treatment EP Receptor inhibitor treatment
NCI-H596
(Non−small 
cell lung carcinoma)
SKOV3
(Ovarian carcinoma)
MZ-CHA-3
(Cholangiocarcinoma)
Untreated
LB919-SCCHN
(Head & neck carcinoma)
 LB188-SAR
(Sarcoma)
 LB1610-MEL
(Melanoma)
0 20 40 60 80 100
A B
C
DM
SO
CA
Y1
05
98
(EP
4 a
gon
ist)
0.00
0.02
0.04
0.06
DM
SO
CA
Y1
05
98
(EP
4 a
gon
ist)
0.0
0.1
0.2
0.3
0.4
N
um
be
r o
f I
D
O
1 
tra
ns
cr
ip
ts
 p
er
 c
el
l 
re
po
rte
d 
to
 4
,0
00
 G
AP
DH
 
tra
ns
cr
ip
ts
U87 Cells A172 CellsD
DM
SO
Ce
lec
oxi
b
CA
Y1
05
98
(EP
4 a
gon
ist)
 
Ce
lec
oxi
b +
 CA
Y1
50
98
(EP
4 a
gon
ist)
0
SKOV3 Cells
**
*
E
0
5
10
15
****
COX-2
0
2
4
6
8
10
Ex
pr
es
sio
n 
of
 C
O
X-
2 
Ex
pr
es
sio
n 
of
 m
PG
ES
1
Ex
pr
es
sio
n 
of
 V
in
cu
lin
IDO1− IDO1+ IDO1− IDO1+
Vinculin
****
mPGES1
0
5
10
15
IDO1− IDO1+
F
All tumor
  lines
Lung 
tumor 
lines
Mutated Nonmutated
P
15/23 
(65%)
21/57 
(37%)
79/138 
(57%)
113/249 
(45%)
0.0136
0.0355
IDO1-positive cell lines
PI3K or/and MAPK
0 20 40 60 80 100
NCI-H596
(Non−small 
cell lung carcinoma)
SKOV3
(Ovarian carcinoma)
MZ-CHA-3
(Cholangiocarcinoma)
Untreated
LB919-SCCHN
(Head & neck carcinoma)
 LB188-SAR
(Sarcoma)
 LB1610-MEL
(Melanoma)
50
100
150
12
0
N
um
be
r o
f  I
D
O
1 
tra
ns
cr
ip
ts
 p
er
 4
,0
00
 
G
AP
DH
 tr
an
sc
rip
ts
 re
po
rte
d 
to
 th
e 
u
n
tre
at
ed
 c
on
di
tio
n 
(%
)
Figure 6.
Involvement of the PGE2 pathway in IDO1 expression by different cancer cell lines. A, Human tumor lines were treated with celecoxib. Quantiﬁcation of
IDO1 was performed by RT-qPCR and reported to the untreated condition for each line (expressed in %). The transcript levels of IDO1 per cell in the untreated
conditions are described in Supplementary Table S1. B, MZ-CHA-3, LB919-SCCHN, LB188-SAR, and NCI-H596 were treated with AH6809 (EP2 inhibitor) while
LB1610-MEL and SKOV3 were treated with GW627368X (EP4 inhibitor). Quantiﬁcation of IDO1 was performed by RT-qPCR. C, SKOV3 cells were treated with
celecoxib at day 0. At dayþ2 cells were treated with the EP4 agonist for 24 hours before IDO1was quantiﬁed by RT-qPCR. D, U87 and A172 glioblastoma cells were
treated 24 hours with an EP4 agonist. E, Tumor lines from the CCLE database were clustered into IDO1-positive and IDO1-negative lines and the expression
of COX-2 and mPGES1 was compared. F, Table derived from the CCLE database illustrating the proportion of IDO1-expressing cell lines bearing mutations
in the PI3K or MAPK pathways. A–D, MeanþSD of triplicates from one out of three experiments. (See also Supplementary Figs. S4 and S5.)
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was required to jump-start constitutive IDO1 expression. We
therefore interrogated the CCLE database asking whether
IDO1-expressing cell lines were enriched in PI3K or MAPK muta-
tions. Indeed, we observed enrichment in MAPK or PI3K muta-
tions in the IDO1-expressing cell lines. This was true in the whole
set of cell lines and was conﬁrmed in the subset of lung cancer, for
which the number of cell lines was large enough (Fig. 6F).
No involvement of STAT3
One of the human tumor lines that we tested above, ovarian
carcinoma SKOV3, was previously analyzed by Litzenburger and
colleagues, who proposed that constitutive IDO1 expression was
driven in this cell line by STAT3 activation, triggered by an
autocrine loop of interleukin-6 (38). In fact, STAT3 has been
described as a downstream effector of tyrosine kinase receptors,
such as the EGF receptor or the IL6 receptor, but it can also be
activated by the EP receptors (39). We therefore knocked down
STAT3 in both SKOV3 and KUL98-MELA cells using a lentiviral
shRNA construct. Although STAT3 was silenced in both cell lines,
we observed no effect on IDO1 expression, neither at the mRNA
level nor at the protein level (Supplementary Fig. S6A and S6C).
Accordingly, IDO1 enzymatic activity was not reduced by STAT3
knockdown, although it was reduced in both cell lines by treat-
ment with celecoxib (Supplementary Fig. S6B and S6D). Litzen-
burger and colleagues observed reduced IDO1 expression in
SKOV3 cells after treatment with AG490, which was used as a
JAK inhibitor. However, AG490 also inhibits EGFR (40) and
thereby may inhibit the MAPK pathway and repress COX-2
expression. We observed that ruxolitinib, a more speciﬁc JAK1/
2 inhibitor, abrogated the active phosphorylated form of STAT3
but did not reduce IDO1 transcripts in both KUL98-MELA and
SKOV3 cells (Supplementary Figs. S1A, S1B, and S6E). Alto-
gether, these results do not support a direct role for STAT3 in
IDO1 expression in SKOV3 and KUL98-MELA, but rather
support the notion that constitutive IDO1 expression is driven
by autocrine PGE2. We do not exclude the possibility that
STAT3 can induce IDO1 expression in speciﬁc contexts, but
we propose that this effect might be indirect through the
induction of COX-2 by STAT3 (41).
COX-2 inhibition promotes rejection of IDO1-expressing
tumors
We set out to assess the relevance of our ﬁndings for cancer
therapy. Because we could not identify a murine tumor line that
expresses IDO1 constitutively, we set up an in vivomodel using the
human ovarian carcinoma line SKOV3 characterized above,
which expresses IDO1 in a constitutive manner that is sensitive
to celecoxib (Supplementary Fig. S7A and S7B). We injected
SKOV3 cells into immunodeﬁcient NOD/Scid/Il-2rg/(NSG)
mice (42). After 10 days, tumors were visible and mice received
an injection of allogeneic human lymphocytes (PBMCs). Mice
were also treated with celecoxib, and tumor growth was moni-
tored (Fig. 7A). In the absence of celecoxib, tumor growth con-
tinued unabated at a rate similar to tumors of mice that did not
receive human lymphocytes, indicating that the antitumor effect
of allogeneic lymphocytes was blocked, possibly because of IDO1
expression by SKOV3 cells (Fig. 7B). In contrast, tumor growth
was controlled in mice that received lymphocytes and celecoxib.
Because the COX-2/PGE2 axismay also favor tumor development
by non-immune pathways such as angiogenesis, we also admin-
istered celecoxib to SKOV3 tumor–bearing mice that did not
receive human lymphocytes. In this setting, celecoxib did not
alter the course of tumor growth (Fig. 7B). In line with the
notion that the tumor rejection promoted by celecoxib resulted
from a blockade of IDO1 expression, we observed an identical
antitumor effect in mice treated with allogeneic lymphocytes
and IDO1 inhibitor epacadostat, which we conﬁrmed can
effectively block IDO1 enzymatic activity and restore prolifer-
ation of T lymphocytes cocultured with SKOV3 cells (Supple-
mentary Fig. S7C and S7D). Conversely, when we repeated this
experiment with IDO1-negative tumor colorectal carcinoma
line LS411N, we observed some immune control with alloge-
neic lymphocytes in untreated mice, in line with the absence of
IDO1 expression, but there was no additional effect of celecoxib
or epacadostat (Fig. 7B, right). These results suggested that
celecoxib treatment of mice bearing SKOV3 tumors repressed
IDO1 expression in these tumors and thereby allowed lympho-
cyte inﬁltration and proliferation in the tumor. To conﬁrm this
interpretation, we ﬁrst excluded a direct effect of celecoxib on
human lymphocytes by measuring their proliferation and cyto-
kine production in vitro in the presence or absence of celecoxib.
No difference was observed in terms of proliferation and Th1
cytokine production, although Th2 cytokine production was
reduced in the presence of celecoxib (Supplementary Fig. S7E
and S7F). In contrast, proliferation and Th1 cytokine produc-
tion were impaired when lymphocytes were cultured in SKOV3-
conditioned medium, but not when they were cultured in
medium conditioned with celecoxib-treated SKOV3 cells (Sup-
plementary Fig. S7E and S7F). This is in line with the effect of
celecoxib on IDO1 expression and tryptophan catabolism in
SKOV3 cells (Supplementary Fig. S7A and S7B). Second, we
tested IDO1 expression by Western blot in SKOV3 tumors
collected from mice at day 7 of the in vivo experiment (Fig.
7C). In mice treated with celecoxib, IDO1 expression was
reduced, particularly in mice that did not receive lymphocytes.
Mice that did receive lymphocytes expressed residual amounts
of IDO1 despite celecoxib. This residual expression, which
probably resulted from IDO1 induction by IFNg produced by
lymphocytes, did not affect lymphocyte activity in this model,
because we observed equal tumor control in mice that received
lymphocytes with celecoxib, IDO1 inhibitor or both (Fig. 7B).
Lastly, we analyzed T-cell inﬁltration in SKOV3 tumors collected
at day 40 of the in vivo experiment. We stained tumor sections
for CD3 and CD8 and observed a higher inﬁltration of both
CD3-positive cells and CD8-positive cells in tumors from mice
treated with celecoxib or epacadostat as compared to untreated
mice (Fig. 7D and E). This was conﬁrmed by RT-qPCR analysis
of additional tumors (Fig. 7F). Altogether, these results con-
ﬁrmed the mechanism whereby celecoxib induced the rejection
of SKOV3 tumors in this model. Celecoxib repressed IDO1
expression in SKOV3 tumor cells, thereby releasing the T-cell
suppression imposed by tryptophan catabolism in the tumor
microenvironment, and unleashing T cells that can now survive
and proliferate at the tumor site to achieve tumor rejection.
Discussion
Certain human tumors of various histotypes express IDO1 in a
constitutive manner, thereby setting up amechanism of innate or
intrinsic immune resistance that can prevent T-cell inﬁltration
resulting in uninﬂamed or "cold" tumors. Such a mechanism
differs from the adaptive immune resistance, initially described in
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human melanoma, in which IDO1 expression is associated with
T-cell inﬁltration and triggered by the interferon-gamma pro-
duced by inﬁltrating T cells. Because immune checkpoint inhibi-
tors act by unleashing existing antitumor T lymphocytes, they are
more efﬁcient in patients bearing T-cell inﬂamed tumors than in
those with uninﬂamed or cold tumors. Deﬁning new approaches
to trigger T-cell inﬁltration in cold tumors will be key to increasing
the efﬁcacy of cancer immunotherapy. This requires a detailed
understanding of the molecular mechanisms responsible for this
lack of T-cell inﬁltration.
Here, we characterized the signaling mechanisms responsible
for constitutive IDO1 expression in a series of human tumors of
various types. We found that constitutive IDO1 expression was
dependent on an autocrine loop of PGE2 production, leading to
activation of the PI3K and PKC pathways and the subsequent
activation of IDO1 transcription by factors such as b-catenin and,
most likely, ETV4. Autocrine PGE2 production depends on con-
stitutive expression of mPGES1 and COX-2. The latter is con-
trolled by the MAPK pathway, which can be activated in tumor
cells by growth factors such as IL1 or EGF, but can also be activated
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Figure 7.
Celecoxib favors immune rejection of
IDO1-expressing human ovarian
carcinoma. A, Scheme of the
experimental procedure detailed in
the Materials and Methods section.
B, Tumor growthwasmeasured twice
a week until mice were sacriﬁced
according to ethical
recommendations. Mean  SEM of 9
mice/group; experiment repeated
3–5 times for SKOV-3, once for
LS411N. C, Tumors collected at dþ7
were frozen, proteins were extracted
and IDO1 expression was tested by
Western blot (repeated 3 times).
D, Illustration of the CD3 and CD8
immunohistochemistry stainings of
frozen sections from one
representative SKOV3 tumor for each
of the indicated experimental
conditions. 60 magniﬁcation
(10 for the inset). E, Quantiﬁcation
by ImageJ software (whole sections)
of the CD3 and CD8 stainings
illustrated on panel D (MeanþSD).
Statistics represent the comparison
between the treated and the
untreated conditions for each speciﬁc
staining. F, Quantitative analysis of
CD3 and CD8 transcripts in RNA from
4 tumors for each condition, collected
in two separate experiments (1 tumor
for the epacadostat condition)
(MeanþSD). Statistics represent the
comparison between the treated and
the untreated conditions for each
speciﬁc gene expression. See also
Supplementary Fig. S7.
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by oncogenic mutations such as BRAF V600E. Indeed, inhibition
ofmutant BRAF inmelanoma line KUL98-MELA suppressed both
COX-2 and IDO1 expression. Our results therefore provide a
conceptual framework to explain the role of COX-2 as a driver
of tumor-induced immunosuppression (20, 21). In Zelenay and
colleagues, inhibition or ablation of COX-2 in a BRAF V600E
mouse melanoma model rendered tumors sensitive to immune
control (20). In Hou and colleagues, PGE2 inactivation sensitized
tumors to immunotherapy (21). Our results suggest that at least
part of the effect reported in these studiesmayhavebeenmediated
by the repression of IDO1 expression in those tumors.
We observed that most of the tumor lines that express IDO1
constitutively also bear oncogenic mutations in one of the sig-
naling pathways involved in the autocrine loop we describe,
including PI3K and MAPK. An analysis of the CCLE database
conﬁrmed that IDO1-expressing tumor lines harboredmutations
in the PI3K or MAPK pathways more frequently than IDO1-
negative lines, suggesting that oncogenic signaling jump-starts
IDO1 expression.
A similar case has been described for PD-L1, another immu-
nosuppressive factor whose expression can either be induced
by interferon-gamma produced by inﬁltrating T cells, resulting
in adaptive immune resistance, or be constitutive, leading to
intrinsic (or innate) immune resistance (19). The mechanisms
responsible for constitutive PD-L1 expression in human
tumors have only begun to be characterized, and appear to
involve the PI3K/AKT axis in glioblastomas (43) and triple-
negative breast carcinomas (44), whereas Hodgkin lympho-
mas express PD-L1 as a result of the ampliﬁcation of the
encoding gene (45).
Our results suggest potential therapeutic avenues that may be
useful to treat cold tumors. Besides inhibitors of IDO1 enzy-
matic activity, which are in phase III of clinical evaluation,
COX-2 inhibitors can prevent IDO1 expression in those
tumors. We validated this prediction using human SKOV3
tumors in NSG mice reconstituted with human allogeneic
lymphocytes. These tumors were not rejected unless mice were
treated with a COX-2 inhibitor or with an IDO1 inhibitor.
Although PGE2 may trigger other immunosuppressive mechan-
isms in different contexts (46), the lack of additive antitumor
effect of targeting both COX-2 and IDO1 supports the notion
that the effect of celecoxib in our model is essentially mediated
by repression of IDO1 expression. Although we did not test the
effect of PI3K, mTOR, MAPK, or BRAF V600E inhibitors in this
in vivomodel, it is possible that IDO1 repression contributes to
the antitumor effects observed with such molecules in other
contexts. PI3K contributes to the induction of long-term
immune tolerance by mouse plasmacytoid dendritic cells
(pDC) that have been exposed to TGFb. PI3K promotes phos-
phorylation of IDO1 by the Fyn tyrosine kinase, thereby induc-
ing a signaling pathway that results in sustained expression of
IDO1 and TGFb (47). PI3K inhibition would therefore not only
reduce IDO1 constitutive expression in cancer cells but also
abrogate tolerance induction by pDCs in the tumor microen-
vironment. This double effect would favor tumor rejection. In
sum, our results further highlight the potential of COX-2 and,
potentially, PI3K inhibitors as useful adjuvants to combine
with cancer immunotherapy.
Imatinib, which is used in the treatment of gastrointestinal
stromal tumors (GIST) for its ability to inhibit oncogenic
signaling due to mutant KIT or PDGFR, also represses IDO1
expression in those tumors and thereby favors their control by
antitumor T lymphocytes (32). In line with our ﬁndings in
other tumor types, oncogenic KIT signaling in GIST involves the
PI3K–AKT–mTOR pathway and culminates in the induction of
ETV4, a transcription factor whose expression is repressed in
imatinib-treated GIST cells. ETV4 binding sites were identiﬁed
in the IDO1 promoter and conﬁrmed to bind ETV4 by chro-
matin immunoprecipitation (32). Hence, ETV4 may link the
PI3K–AKT–mTOR pathway to the activation of the IDO1 pro-
moter (Fig. 2). However, other transcription factors down-
stream of mTOR may also play a role.
Our results also indicate that b-catenin likely links the PKC-
GSK3b pathway to the activation of the IDO1 promoter (Fig. 2).
In melanoma, intrinsic b-catenin signaling is a key factor
mediating immune resistance and lack of T-cell inﬁltration
(33, 48). This study identiﬁed ATF3-mediated repression of
chemokine CCL4 as responsible for the lack of recruitment
of CD103þ dendritic cells in the tumor and the resulting
lack of T-cell inﬁltration. Based on our results, we speculate
that b-catenin signaling also prevents T-cell inﬁltration by
inducing constitutive expression of IDO1.
By deciphering the oncogenic signaling pathways responsible
for constitutive IDO1 expression in human tumors, our results
shed light on themechanisms responsible for the problemof cold
tumors, which are not inﬁltrated by T lymphocytes and therefore
fail to respond to immunotherapy. Our results also suggest
clinically applicable therapeutic options to counteract such
immunosuppressive mechanisms.
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